U.S Patent System to Transform From "First to Invent" to "First to File" - AVI BioPharma and XOMA Look to Benefit

The Paragon Report Provides Stock Research on AVI BioPharma and XOMA


NEW YORK, NY--(Marketwire -05/04/12)- Biotech stocks have continued to provide investors with strong gains in 2012. The iShares NASDAQ Biotechnology Index (IBB) is up nearly 20 percent year-to-date. The passage of the America Invents Act will look to benefit the Biotechnology Industry going forward "by enhancing patent quality and the efficiency, objectivity, predictability and transparency of the U.S. patent system," BIO President and CEO Jim Greenwood stated in a press release. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on AVI BioPharma, Inc. (AVII - News) and XOMA Corporation (XOMA - News).

Access to full reports can be found at:

"Small biotechnology companies rely heavily on their patents to attract investment," and "they will benefit from the improvements to our nation's patent system made by this legislation," added Greenwood. The America Invents Act (AIA) will shift the patent system from a "first to invent" to a "first to file" system, the first major change to the patent system in over 60 years. Under the "first to file" system the first inventor to file for a patent will be awarded priority, regardless if the inventor was the first to invent it. Most major countries are already following the "first to file" patent system.

Paragon Report releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.ParagonReport.com and get exclusive access to our numerous stock reports and industry newsletters.

AVI BioPharma is focused on the discovery and development of novel RNA-based therapeutics for rare and infectious diseases, as well as other select disease targets. Applying pioneering technologies developed and optimized by AVI, the Company is able to target a broad range of diseases and disorders through distinct RNA-based mechanisms of action. The company recently released positive results for their drug Esteplirsen in the treatment of Duchenne Muscular Dystrophy.

XOMA is a biopharmaceutical company focused on the discovery, development and manufacture of therapeutic antibodies designed to treat autoimmune, infectious, inflammatory and oncological diseases. The Company recently announced that they will host a webcast conference call on Tuesday, May 8, 2012 at 4:30 p.m. Eastern time to discuss first quarter 2012 financial results and provide a detailed overview on the study designs for gevokizumab's global Phase 3 clinical program.

Paragon Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Paragon Report has not been compensated by any of the above-mentioned companies. We act as independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:


View Comments (0)